Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of JTE-051 Administered for 12 Weeks in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR-PS)

NCT03358290 is registered in ClinicalTrials.gov with Akros Pharma Inc. as lead sponsor.

NCT NCT03358290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03358290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of JTE-051 Administered for 12 Weeks in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR-PS)
Lead sponsor
Akros Pharma Inc.
Phase
Phase 2
Overall status
Terminated
Start date
November 10, 2017
Completion date
October 29, 2018
Enrollment
13 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis, skin diseases